TW200700068A - Phthalazine, aza-and diaza-phthalazine compounds and methods of use - Google Patents

Phthalazine, aza-and diaza-phthalazine compounds and methods of use

Info

Publication number: TW200700068A
Authority: TW; Taiwan
Prior art keywords: compounds; phthalazine; diaza; aza; methods
Prior art date: 2005-03-03

Application number

TW095107308A

Other languages

English (en)

Inventor

Andrew Tasker

Da-Wei Zhang

Guo-Qiang Cao

Partha Pratim Chakrabarti

James Richard Falsey

Bradley J Herberich

Randall W Hungate

Liping H Pettus

Anthony Reed

Robert M Rzasa

Kelvin K C Sham

Maya C Thaman

Shimin Xu

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-03

Filing date

2006-03-03

Publication date

2007-01-01

2006-03-03 Application filed by Amgen Inc filed Critical Amgen Inc

2007-01-01 Publication of TW200700068A publication Critical patent/TW200700068A/zh

Links

238000000034 method Methods 0.000 title abstract 2
TTZXCJXSLQFVBW-UHFFFAOYSA-N 1,2,3,4-benzotetrazine Chemical class N1=NN=NC2=CC=CC=C21 TTZXCJXSLQFVBW-UHFFFAOYSA-N 0.000 title 1
XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 1
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
206010061218 Inflammation Diseases 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
230000004054 inflammatory process Effects 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
238000011282 treatment Methods 0.000 abstract 2
108091000080 Phosphotransferase Proteins 0.000 abstract 1
102000001253 Protein Kinase Human genes 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Virology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Obesity (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)

TW095107308A 2005-03-03 2006-03-03 Phthalazine, aza-and diaza-phthalazine compounds and methods of use TW200700068A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US65900305P	2005-03-03	2005-03-03
US11/367,123 US7759337B2 (en)	2005-03-03	2006-03-02	Phthalazine compounds and methods of use

Publications (1)

Publication Number	Publication Date
TW200700068A true TW200700068A (en)	2007-01-01

Family

ID=36648799

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095107308A TW200700068A (en)	2005-03-03	2006-03-03	Phthalazine, aza-and diaza-phthalazine compounds and methods of use

Country Status (9)

Country	Link
US (1)	US7759337B2 (zh)
EP (1)	EP1856058B1 (zh)
JP (1)	JP5536982B2 (zh)
AR (1)	AR053443A1 (zh)
AU (1)	AU2006218449B2 (zh)
CA (1)	CA2599403C (zh)
MX (1)	MX2007010699A (zh)
TW (1)	TW200700068A (zh)
WO (1)	WO2006094187A2 (zh)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102005038947A1 (de) *	2005-05-18	2006-11-30	Grünenthal GmbH	Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE102005026194A1 (de) *	2005-06-06	2006-12-07	Grünenthal GmbH	Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
TWI403320B (zh) *	2005-12-16	2013-08-01	Infinity Discovery Inc	用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
US7989461B2 (en)	2005-12-23	2011-08-02	Amgen Inc.	Substituted quinazolinamine compounds for the treatment of cancer
JP2009524637A (ja) *	2006-01-27	2009-07-02	ファイザー・プロダクツ・インク	アミノフタラジン誘導体化合物
US20090099175A1 (en) *	2006-03-01	2009-04-16	Arrington Mark P	Phosphodiesterase 10 inhibitors
WO2007140439A2 (en) *	2006-05-31	2007-12-06	Abbott Laboratories	Compounds as cannabinoid receptor ligands and uses thereof
US8841334B2 (en) *	2006-05-31	2014-09-23	Abbvie Inc.	Compounds as cannabinoid receptor ligands and uses thereof
US8101612B2 (en) *	2006-09-05	2012-01-24	Amgen Inc.	Phthalazine compounds and methods of use
CA2669687C (en)	2006-11-15	2013-09-10	Forest Laboratories Holdings Limited	Phthalazine derivatives
CA2681162C (en)	2007-03-15	2015-11-24	Novartis Ag	Benzyl and pyridine derivatives as modulators of hedgehog pathway
EP2002835A1 (en)	2007-06-04	2008-12-17	GenKyo Tex	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
JP2010522760A (ja)	2007-03-28	2010-07-08	アボット・ラボラトリーズ	カンナビノイド受容体リガンドとしての１，３−チアゾール−２（３ｈ）−イリデン化合物
US7872033B2 (en) *	2007-04-17	2011-01-18	Abbott Laboratories	Compounds as cannabinoid receptor ligands
WO2008136948A1 (en) *	2007-05-07	2008-11-13	Amgen Inc.	Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use
MX2009012374A (es) *	2007-05-18	2009-12-01	Abbott Lab	Compuestos novedosos como ligandos del receptor de canabinoides.
US9193713B2 (en) *	2007-10-12	2015-11-24	Abbvie Inc.	Compounds as cannabinoid receptor ligands
TW200942535A (en)	2008-03-11	2009-10-16	Abbott Lab	Novel compounds as cannabinoid receptor ligands
US8367671B2 (en)	2008-03-21	2013-02-05	Amgen Inc.	Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
EP2113503A1 (en)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
US20100041663A1 (en)	2008-07-18	2010-02-18	Novartis Ag	Organic Compounds as Smo Inhibitors
EP2334673A1 (en)	2008-08-29	2011-06-22	Amgen Inc.	PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
US8455495B2 (en)	2008-08-29	2013-06-04	Amgen Inc.	Pyridazino-pyridinone compounds and methods of use
US8846730B2 (en) *	2008-09-08	2014-09-30	Abbvie Inc.	Compounds as cannabinoid receptor ligands
MY148558A (en)	2008-09-11	2013-04-30	Amgen Inc	Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
TW201016692A (en) *	2008-09-16	2010-05-01	Abbott Lab	Novel compounds as cannabinoid receptor ligands
EP2165707A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as nadph oxidase inhibitors
US8772481B2 (en) *	2008-10-10	2014-07-08	Amgen Inc.	Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
US8497269B2 (en)	2008-10-10	2013-07-30	Amgen Inc.	Phthalazine compounds as p38 map kinase modulators and methods of use thereof
PA8854001A1 (es) *	2008-12-16	2010-07-27	Abbott Lab	Compuestos novedosos como ligandos de receptores de canabinoides
JP2012522004A (ja) *	2009-03-27	2012-09-20	アボット・ラボラトリーズ	カンナビノイド受容体リガンドである化合物
EP2305679A1 (en)	2009-09-28	2011-04-06	GenKyoTex SA	Pyrazoline dione derivatives as nadph oxidase inhibitors
WO2011063233A1 (en)	2009-11-23	2011-05-26	Amgen Inc.	Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504330A1 (en)	2009-11-23	2012-10-03	Amgen Inc.	Amino heteroaryl compounds as beta-secretase modulators and methods of use
CN102812003B (zh)	2009-12-18	2015-01-21	欧洲筛选有限公司	吡咯烷羧酸衍生物、药物组合物以及在代谢紊乱中作为g-蛋白偶联受体43(gpr43)激动剂使用的方法
CA2788363A1 (en)	2010-01-19	2011-07-28	Amgen Inc.	Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2361912A1 (en) *	2010-02-18	2011-08-31	GenKyoTex SA	Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2547685A1 (en)	2010-03-15	2013-01-23	Amgen Inc.	Spiro-tetracyclic ring compounds as beta - secretase modulators
US8497264B2 (en)	2010-03-15	2013-07-30	Amgen Inc.	Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US8921363B2 (en)	2010-08-05	2014-12-30	Amgen Inc.	Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
US8957083B2 (en)	2010-11-23	2015-02-17	Amgen Inc.	Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US9346827B2 (en)	2011-02-07	2016-05-24	Amgen Inc.	5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2675810A1 (en)	2011-02-15	2013-12-25	Amgen Inc.	Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012150221A2 (de)	2011-05-04	2012-11-08	Bayer Cropscience Ag	Neue halogenierte benzylalkoholester der cyclopropancarbonsäure als schädlingsbekämpfungsmittel
WO2012150208A1 (de)	2011-05-04	2012-11-08	Bayer Cropscience Ag	Verwendung von substituierten benzylalkoholestern der cyclopropancarbonsäure zur bekämpfung von insektizid-resistenten insekten
WO2013044092A1 (en)	2011-09-21	2013-03-28	Amgen Inc.	Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US10531655B2 (en)	2011-12-02	2020-01-14	The Regents Of The University Of California	Reperfusion protection solution and uses thereof
JPWO2013161871A1 (ja) *	2012-04-25	2015-12-24	興和株式会社	Ｔｌｒ阻害作用を有するチオフェン誘導体
SG11201407919WA (en) *	2012-05-31	2014-12-30	Phenex Pharmaceuticals Ag	Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
US9056860B2 (en) *	2012-06-05	2015-06-16	Gilead Pharmasset Llc	Synthesis of antiviral compound
FR2992316A1 (fr) *	2012-06-22	2013-12-27	Sanofi Sa	Derives de pyrimidinones, leur preparation et leur application en therapeutique
AP2015008433A0 (en) *	2012-11-09	2015-05-31	Jacobus Pahrmaceutical Company Inc	Heteroaryl derivatives and uses thereof
EP2917200A1 (en)	2012-11-09	2015-09-16	Jacobus Pharmaceutical Company, Inc.	Aryl derivatives and uses thereof
WO2014078314A1 (en)	2012-11-15	2014-05-22	Amgen Inc.	Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CN105916500A (zh)	2013-11-27	2016-08-31	欧洲筛选有限公司	用于治疗炎性疾病的化合物、药物组合物和方法
US20180093956A1 (en) *	2015-02-06	2018-04-05	Abbvie Inc.	Substituted phthalazines
US10912846B2 (en)	2015-05-29	2021-02-09	Arizona Board Of Regents On Behalf Of The University Of Arizona	Molecular probes for chemiluminescence imaging and in vivo detection of target molecules
WO2018082814A1 (en)	2016-11-07	2018-05-11	Metriopharm Ag	Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
US20210130291A1 (en) *	2016-12-22	2021-05-06	The National Institute for Biotechnology in the Negev Ltd.	Methods for treating diabetes using vdac1 inhibitors
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112020006677A2 (pt)	2017-10-05	2020-10-06	Fulcrum Therapeutics, Inc.	uso de inibidores p38 para reduzir a expressão de dux4
EP3479843A1 (en)	2017-11-01	2019-05-08	GenKyoTex Suisse SA	Use of nox inhibitors for treatment of cancer
GB201810669D0 (en) *	2018-06-28	2018-08-15	Stiftelsen Alzecure	New compounds
AR116635A1 (es) *	2018-10-15	2021-05-26	Servier Lab	Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
CN111100042B (zh) *	2019-11-18	2022-05-31	苏州诚和医药化学有限公司	一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
CN111018750B (zh) *	2019-12-19	2022-05-27	苏州诚和医药化学有限公司	一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法
WO2022017339A1 (zh) *	2020-07-20	2022-01-27	江苏恒瑞医药股份有限公司	稠合哒嗪类衍生物、其制备方法及其在医药上的应用
KR20230098078A (ko) *	2021-12-24	2023-07-03	제일약품주식회사	신규한 바이사이클릭 헤테로사이클릴 화합물 및 이의 용도
EP4637746A1 (en) *	2022-12-19	2025-10-29	Merck Sharp & Dohme LLC	6,6 bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
CN116046958B (zh) *	2023-03-28	2023-07-07	上海赛默罗生物科技有限公司	酞嗪异噁唑类药物中有关物质的检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4223142A (en) *	1976-06-16	1980-09-16	E. R. Squibb & Sons, Inc.	Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters
US4665181A (en) *	1984-05-17	1987-05-12	Pennwalt Corporation	Anti-inflammatory phthalazinones
EP0600831A1 (de) *	1992-11-27	1994-06-08	Ciba-Geigy Ag	Phthalazinonderivate
DE69533057T2 (de) *	1994-08-09	2005-06-16	Eisai Co., Ltd.	Kondensierte pyridazinverbindungen
JP3919835B2 (ja) *	1994-08-09	2007-05-30	エーザイ・アール・アンド・ディー・マネジメント株式会社	縮合ピリダジン系化合物
AU702887B2 (en)	1995-10-31	1999-03-11	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
JPH107572A (ja) *	1996-06-17	1998-01-13	Sumitomo Pharmaceut Co Ltd	腫瘍壊死因子産生阻害剤
CN1121220C (zh) *	1996-08-20	2003-09-17	卫材株式会社	稠合哒嗪系化合物的勃起机能不全症治疗剂
ATE236134T1 (de)	1996-12-18	2003-04-15	Neurogen Corp	Isoquinolinamin und phtalazinamin derivate, die reagieren mit crf rezeptoren
JPH10330377A (ja) *	1997-06-02	1998-12-15	Kyowa Hakko Kogyo Co Ltd	ピペリジン誘導体
IT1296984B1 (it) *	1997-12-19	1999-08-03	Zambon Spa	Derivati ftalazinici inibitori della fosfodiesterasi 4
AU755361B2 (en) *	1998-02-19	2002-12-12	Eisai R&D Management Co., Ltd.	Phthalazine derivatives and remedies for erectile dysfunction
JP3947627B2 (ja) *	1998-02-19	2007-07-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	フタラジン誘導体および勃起機能不全症治療剤
AR023659A1 (es) *	1998-09-18	2002-09-04	Vertex Pharma	Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
JP2000191659A (ja) *	1999-01-04	2000-07-11	Sumitomo Pharmaceut Co Ltd	腫瘍壊死因子産生阻害剤
JP2002539187A (ja) *	1999-03-17	2002-11-19	アストラゼネカアクチボラグ	アミド誘導体
JP4649046B2 (ja)	1999-05-21	2011-03-09	ブリストル−マイヤーズスクイブカンパニー	キナーゼのピロロトリアジン阻害剤
RU2167659C1 (ru)	2000-08-02	2001-05-27	Закрытое акционерное общество "Центр современной медицины "Медикор"	Способ коррекции иммунной системы живого организма
US7186720B2 (en) *	2001-04-20	2007-03-06	Sanofi-Aventis	Tetrahydropyridyl-alkyl-heterocycles, method for preparing the same and pharmaceutical compositions containing the same
US20030073692A1 (en) *	2001-08-07	2003-04-17	Pharmacia & Upjohn S.P.A.	Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0500200A2 (hu)	2002-01-17	2005-07-28	Neurogen Corporation	Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények
US20040018458A1 (en) *	2002-05-17	2004-01-29	Hajime Nakagawa	Photothermographic material
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
CA2509616A1 (en)	2002-12-13	2004-07-01	Neurogen Corporation	Combination therapy for the treatment of pain
US7429597B2 (en) *	2002-12-23	2008-09-30	Boehringer Ingelheim Pharma Gmbh & Co., Kg	Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
GB0310726D0 (en)	2003-05-09	2003-06-11	Merck Sharp & Dohme	Therapeutic agents
DE10333755A1 (de)	2003-07-24	2005-03-31	Basf Ag	Verfahren zur Dehydrierung von Carbonylverbindungen
EP1687284B1 (en) *	2003-07-25	2008-10-29	Novartis AG	p-38 KINASE INHIBITORS
GB0417905D0 (en)	2004-08-11	2004-09-15	Novartis Ag	Organic compounds
DE202008015289U1 (de)	2008-11-18	2010-04-08	Voss Automotive Gmbh	Leitungsverbinder für Medienleitungen

2006
- 2006-03-02 US US11/367,123 patent/US7759337B2/en active Active
- 2006-03-03 WO PCT/US2006/007583 patent/WO2006094187A2/en not_active Ceased
- 2006-03-03 AU AU2006218449A patent/AU2006218449B2/en not_active Expired
- 2006-03-03 AR ARP060100800A patent/AR053443A1/es unknown
- 2006-03-03 MX MX2007010699A patent/MX2007010699A/es active IP Right Grant
- 2006-03-03 JP JP2007558261A patent/JP5536982B2/ja not_active Expired - Lifetime
- 2006-03-03 TW TW095107308A patent/TW200700068A/zh unknown
- 2006-03-03 EP EP06736839.9A patent/EP1856058B1/en not_active Expired - Lifetime
- 2006-03-03 CA CA2599403A patent/CA2599403C/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU2006218449A1 (en)	2006-09-08
EP1856058B1 (en)	2014-09-03
AR053443A1 (es)	2007-05-09
JP5536982B2 (ja)	2014-07-02
MX2007010699A (es)	2007-10-12
JP2008531723A (ja)	2008-08-14
US20060199817A1 (en)	2006-09-07
AU2006218449B2 (en)	2009-12-03
CA2599403C (en)	2011-10-04
EP1856058A2 (en)	2007-11-21
WO2006094187A3 (en)	2008-03-20
CA2599403A1 (en)	2006-09-08
US7759337B2 (en)	2010-07-20
WO2006094187A2 (en)	2006-09-08

Publication	Publication Date	Title
TW200700068A (en)	2007-01-01	Phthalazine, aza-and diaza-phthalazine compounds and methods of use
WO2008045393A3 (en)	2008-06-12	Imidazo- and triazolo-pyridine compounds and methods of use therof
WO2007124181A3 (en)	2007-12-21	Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
WO2006039718A3 (en)	2006-07-13	Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
WO2007022380A3 (en)	2007-06-21	Bis-aryl amide compounds and methods of use
WO2007059257A8 (en)	2008-06-19	N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
TW200728305A (en)	2007-08-01	Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
MY148851A (en)	2013-06-14	Dihydropyridine derivatives as useful as protein kinase inhibitors
ZA200802725B (en)	2009-10-28	Novel 1-AZA bicycloalkyl derivatives for the treatment of psychotic and neurodegenerative disorders
WO2007076092A3 (en)	2007-11-15	Nitrogen- containing bicyclic hetroaryl compounds for the treatment of raf protein kinase-mediated diseases
WO2006119504A3 (en)	2009-06-11	Fused heterocyclic compounds, and compositions and uses thereof
TW200800968A (en)	2008-01-01	Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
MX2009003981A (es)	2009-04-27	Agentes moduladores del receptor de calcio.
NO20091052L (no)	2009-04-06	Diaryleterderivater og anvendelser derav
ATE478863T1 (de)	2010-09-15	Heterotetracyclische verbindungen als tpo- mimetica
MY153719A (en)	2015-03-13	Prokineticin 1 receptor antagonists
WO2007079163A3 (en)	2007-08-30	Prokineticin 1 receptor antagonists
TW200716566A (en)	2007-05-01	Prokineticin 2 receptor antagonists
NO20075477L (no)	2007-12-13	Tetrahydro-pyridoazepin-8-one og beslektede forbindelser for behandling av schizofreni
BR0318521A (pt)	2006-09-12	arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
WO2006055434A3 (en)	2007-07-05	Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
TW200801018A (en)	2008-01-01	6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
ATE467636T1 (de)	2010-05-15	Pyrazoloä3 , 4-düazepinderivate als histamin-h3- antagonisten
ATE445617T1 (de)	2009-10-15	Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
ATE501124T1 (de)	2011-03-15	Phthalazin-, aza- und diazaphthalazinverbindungen und anwendungsverfahren